Clinical Trial Update: A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the long-term safety of BLI5100 in patients with gastroesophageal reflux disease (including non-erosive reflux disease and erosive eso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease
• Non-erosive Reflux Disease

Drugs mentioned

• BLI5100

Snippet

Sponsor: Braintree Laboratories | Conditions: Non-erosive Reflux Disease, Erosive Esophagitis | Phase 3 | Status: COMPLETED